57
Participants
Start Date
September 2, 2013
Primary Completion Date
January 7, 2015
Study Completion Date
September 25, 2019
Avelumab 3 mg/kg
Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
Avelumab 10 mg/kg
Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg once every 2 weeks in the dose- escalation cohort and expansion cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
Avelumab 20 mg/kg
Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg once every 2 weeks in the dose- escalation cohort until disease progression, unacceptable toxicity or withdrawal from the study or study drug occurred.
Research site, Darmstadt
Merck KGaA, Darmstadt, Germany
INDUSTRY